Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders

Bibliography

• Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008;122:S1-84
   PubMed Web of Science ®Google Scholar
• McCrory DC, Williams JW, Dolor RJ, et al. Management of allergic rhinitis in the working-age population. Evidence Report/Technology Assessment Number 67. Rockville, MD; 2003
   Google Scholar
• House of Lords Select Committee on Science and Technology. Allergy. Sixth report, session 2006-07. London: the stationary office; 2007
   Google Scholar
• Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004;24:758-64
   PubMed Web of Science ®Google Scholar
• Zhang L, Han D, Huang D, et al. Prevalence of self-reported allergic rhinitis in eleven major cities in China. Int Arch Allergy Immunol 2009;149:47-57
   PubMed Web of Science ®Google Scholar
• Long A, McFadden C, DeVine D, et al. Management of allergic and nonallergic rhinitis. Evidence Report/Technology Assessment No. 54. AHRQ Pub No 02-E024. Rockville, MD: agency for healthcare research and quality; 2002
   Google Scholar
• Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997;77(4):1033-79
   PubMed Web of Science ®Google Scholar
• Wuthrich B, Brignoli R, Canevascini M, et al. Epidemiological survey in hay fever patients: symptom prevalence and severity and influence on patient management. Schweizer Med Wochenschr 1998;128:139-43
   PubMedGoogle Scholar
• Togias A. Unique mechanistic features of allergic rhinitis. J Allergy Clin Immunol 2000;105:S599-604
   PubMed Web of Science ®Google Scholar
• White MV, Kaliner MA. Mediators of allergic rhinitis. J Allergy Clin Immunol 1992;90:699-704
   PubMed Web of Science ®Google Scholar
• Hansen I, Klimek L, Mösges R, Hörmann K. Mediators of inflammation in the early and late phase of allergic rhinitis. Curr Opin Allergy Clin Immunol 2004;4(3):159-63
   PubMed Web of Science ®Google Scholar
• Gelfand EW. Role of histamine in the pathophysiology of asthma: immunomodulatory and anti-inflammatory activities of H1-receptor antagonists. Am J Med 2002;113:S2-7
   PubMed Web of Science ®Google Scholar
• Taylor-Clark TE. Insights into the mechanisms of histamine-induced inflammation in the nasal mucosa. Pulm Pharmacol Ther 2008;21(3):455-60
   PubMed Web of Science ®Google Scholar
• Meltzer EO. An overview of current pharmacotherapy in perennial. rhinitis 1995;95:1097-110
   Google Scholar
• Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the joint task force on practice parameters in allergy, asthma, and immunology. American academy of allergy, asthma and immunology. Ann Allergy Asthma Immunol 1998;81(5):478-518
   PubMed Web of Science ®Google Scholar
• International Rhinitis Management Working Group. International consensus report on the diagnosis and management of rhinitis. Allergy 1994;49:S1-34
   PubMed Web of Science ®Google Scholar
• van Cauwenberge P, Bachert C, Passalacqua G, et al. European academy of allergology and clinical immunology: consensus statement on the treatment of allergic rhinitis. Allergy 2000;55:116-34
   PubMed Web of Science ®Google Scholar
• Kay GG. The effects of antihistamines on cognition and performance. J Allergy Clin Immunol 2000;105(6):S622-7
   PubMed Web of Science ®Google Scholar
• Leurs R, Church MK, Taglialatela M. H1 antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002;32:489-98
   PubMed Web of Science ®Google Scholar
• DaBuske L, Kowal K. Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep 2009;9:140-8
   PubMed Web of Science ®Google Scholar
• Allegra [prescribing information]. Bridgewater (NJ): sanofi-aventis US, LLC, 2008
   Google Scholar
• Devillier P, Roche N, Faisy C. Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine, and levocetirizine: a comparative review. Clin Pharmacokinet 2008;47(4):217-30
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Tosca MA, Cosentino C, et al. Effects of fexofenadine and other antihistamines on components of the allergic response: adhesion molecules. J Allergy Clin Immunol 2003;112:S78-82
   PubMedGoogle Scholar
• Chen C. Some pharmacokinetic aspects of the lipophilic terfenadine and zwitterionic fexofenadine in humans. Drugs R D 2007;8(5):301-14
   PubMedGoogle Scholar
• Triggiani M, Gentile M, Secondo A, et al. Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. J Immunol 2001;166:4083-91
   PubMed Web of Science ®Google Scholar
• Asano K, Kanai K, Suzaki H. Suppressive activity of fexofenadine hydrochloride on the production of eosinophil chemoattractants from human nasal fibroblasts in vitro. Arzneimittelforschung 2004;54:436-43
   PubMed Web of Science ®Google Scholar
• Asano K, Kanai K, Suzaki H. Suppressive activity of fexofenadine hydrochloride on thymus- and activation-regulated chemokine production from human peripheral blood leukocytes in response to antigenic stimulation in vitro. Int Arch Allergy Immunol 2004;133:267-75
   PubMed Web of Science ®Google Scholar
• Sandoval-López G, Teran LM. TARC: novel mediator of allergic inflammation. Clin Exp Allergy 2001;31:1809-12
   PubMed Web of Science ®Google Scholar
• Juergens UR, Gillissen A, Uen S, et al. New evidence of H1-receptor independent COX-2 inhibition by fexofenadine HCl in vitro. Pharmacology 2006;78:129-35
   PubMed Web of Science ®Google Scholar
• Asano K, Kanai K, Furuta A, et al. Suppressive activity of fexofenadine hydrochloride on nitric oxide production in-vitro and in-vivo. J Pharm Pharmacol 2007;59:1389-95
   PubMed Web of Science ®Google Scholar
• Tateishi T, Miura M, Suzuki T, Uno T. The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers. Br J Clin Pharmacol 2008;65(5):693-700
   PubMed Web of Science ®Google Scholar
• Molimard M, Diquet B, Benedetti MS. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol 2004;18:399-411
   PubMed Web of Science ®Google Scholar
• Kim KA, Park PW, Park JY. Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers. Eur J Clin Pharmacol 2009; doi 10.1007/s00228-009-0627-6
   Google Scholar
• Wang Z, Hamman MA, Huang SM, et al. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002;71:414-20
   PubMed Web of Science ®Google Scholar
• Hamman MA, Bruce MA, Haehner-Daniels BD, et al. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 2001;69:114-21
   PubMed Web of Science ®Google Scholar
• Lemma GL, Wang Z, Hamman MA, et al. The effect of short- and long-term administration on verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther 2006;79:218-30
   PubMed Web of Science ®Google Scholar
• Robbins DK, Castles MA, Pack DJ, et al. Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers. Biopharm Drug Dispos 1998;19:455-63
   PubMed Web of Science ®Google Scholar
• Miura M, Uno T, Tateishi T, Suzuki T. Pharmacokinetics of fexofenadine enantiomers in healthy subjects. Chirality 2007;19:223-7
   PubMed Web of Science ®Google Scholar
• Dresser GK, Kim RB, Bailey DG. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin Pharmacol Ther 2005;77:170-7
   PubMed Web of Science ®Google Scholar
• Kamath AV, Yao M, Zhang Y, Chong S. Effect of fruit juices on the oral bioavailability of fexofenadine in rats. J Pharm Sci 2005;94(2):233-9
   PubMed Web of Science ®Google Scholar
• Golightly LK, Greos LS. Second-generation antihistamines: actions and efficacy in the management of allergic disorders. Drugs 2005;65:341-84
   PubMed Web of Science ®Google Scholar
• Tahara H, Kusahara H, Fuse E, et al. P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. Drug Metab Dispos 2005;33:963-8
   PubMed Web of Science ®Google Scholar
• Gelfand EW. Inflammatory mediators in allergic rhinitis. J Allergy Clin Immunol 2004;114(5):S135-8
   PubMed Web of Science ®Google Scholar
• Yanai K, Ryu JH, Watanabe T, et al. Histamine H1 receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography. Br J Pharmacol 1995;116:1649-55
   PubMed Web of Science ®Google Scholar
• Tashiro M, Sakurada Y, Iwabuchi K, et al. Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol 2004;44:890-900
   PubMed Web of Science ®Google Scholar
• Obradovic T, Dobson GG, Shingaki T, et al. Assessment of the first and second generation antihistamines brain penetration and role of p-glycoprotein. Pharm Res 2007;24(2):318-27
   PubMed Web of Science ®Google Scholar
• Gillman S, Gillard M, Benedetti MS. The concept of receptor occupancy to predict clinical efficacy: a comparison of second generation H1 antihistamines. Allergy Asthma Proc 2009; doi:10.2500/aap.2009.30.3226
   PubMedGoogle Scholar
• Howarth PH, Stern MA, Roi L, et al. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999;104(5):927-33
   PubMed Web of Science ®Google Scholar
• Horak F, Stübner A, Zieglmayer R, et al. Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol 2001;125:73-9
   PubMed Web of Science ®Google Scholar
• Horak F, Zieglmayer PU, Zieglmayer R, et al. Levocetirizine has a longer duration of action on improving nasal symptoms score than fexofenadine after single administration. Br J Clin Pharmacol 2005;60:24-31
   PubMed Web of Science ®Google Scholar
• Anthes JC, Gilchrest H, Richard C, et al. Biochemical characterization of desloratadine, a potent antagonist of the human histamines H1 receptor. Eur J Pharmacol 2002;449:229-37
   PubMed Web of Science ®Google Scholar
• Meeves SG, Appajosyula S. Efficacy and safety profile of fexofenadine HCl: A unique therapeutic option in H1-receptor antagonist treatment. J Allergy Clin Immunol 2003;112:S69-77
   PubMedGoogle Scholar
• van Cawenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120mg, loratadine 10mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 2000;30:891-99
   PubMed Web of Science ®Google Scholar
• Hampel FC, Kittner B, van Bavel JH. Safety and tolerability of fexofenadine hydrochloride, 15 and 30 mg, twice daily in children aged 6 months to 2 years with allergic rhinitis. Ann Allergy Asthma Immunol 2007;99:549-54
   PubMed Web of Science ®Google Scholar
• Sorkin EM, Heel RC. Terfenadine: a review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1985;29(1):34-56
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Schoenwetter WF, Nathan RA, et al. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997;79:443-8
   PubMed Web of Science ®Google Scholar
• Pratt C, Brown AM, Rampe D, et al. Cardiovascular safety of fexofenadine HCl. Clin Exp Allergy 1999;29(Suppl 3):212-6
   PubMed Web of Science ®Google Scholar
• Liu H, Zheng Q, Farley JM. Antimustcarinic actions of antihistamines on the heart. J Biomed Sci 2006;13:395-401
   PubMed Web of Science ®Google Scholar
• Vacchiano C, Moore J, Rice GM, Crawley G. Fexofenadine effects on cognitive performance in aviators at ground level and simulated altitude. Aviat Space Environ Med 2008;79(8):754-60
   PubMed Web of Science ®Google Scholar
• Clark MJ, Million RP. Allergic rhinitis: market evolution. Nat Rev Drug Discov 2009;8:271-2
   PubMed Web of Science ®Google Scholar
• Gupta S, Banfield C, Kantesaria B, et al. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Clin Ther 2001;23:451-66
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Walker A, Hoffer C, et al. Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination. J Clin Pharmacol 2005;45:79-88
   PubMed Web of Science ®Google Scholar
• Banfield C, Gupta S, Marino M, et al. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin Pharmacokinet 2002;41:311-8
   PubMed Web of Science ®Google Scholar
• Stoltz M, Arumugham T, Lippert C, et al. Effect of food on the bioavailability of fexofenadine hydrochloride (MDL 16455A). Biopharm Drug Dispos 1997;18:645-8
   PubMed Web of Science ®Google Scholar
• Russell T, Stoltz M, Weir S. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin Pharmacol Ther 1998;64:612-21
   PubMed Web of Science ®Google Scholar
• Robertson SM, Davey RT, Voell J, et al. Effect of Ginkgo biloba extract on lopinavir, midazolam, and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin 2008;24:591-9
   PubMed Web of Science ®Google Scholar
• Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002;71:11-20
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Uno T, Sugawara K, et al. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther 2005;77:17-23
   PubMed Web of Science ®Google Scholar
• Shimizu M, Uno T, Sugawara K, et al. Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol 2006;61:538-44
   PubMed Web of Science ®Google Scholar
• Bradley CM, Nicholson AN. Studies on the central effects of the H1-antagonist, loratadine. Eur J Clin Pharmacol 1987;32:419-21
   PubMed Web of Science ®Google Scholar
• Bender BG, Berning S, Dudden R, et al. Sedation and performance impairment of diphenhydramine and second-generation antihistamines: a meta-analysis. J Allergy Clin Immunol 2003;111:770-6
   PubMed Web of Science ®Google Scholar
• Shamsi Z, Hindmarch I. Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios. Hum Psychopharmacol Clin Exp 2000;15:S3-30
   PubMed Web of Science ®Google Scholar
• Layton D, Wilton L, Boshier A, et al. Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription-event monitoring study in England. Drug Saf 2006;29(10):897-909
   PubMed Web of Science ®Google Scholar
• Salmun LM, Lorber R. 24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis. BMC Fam Prac 2002;3:14
   PubMedGoogle Scholar
• Hampel F, Ratner P, Mansfield L, et al. Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003;91(4):354-61
   PubMed Web of Science ®Google Scholar
• Orzechowski RF, Currie DS, Valancius CA. Comparative anticholinergic activities of 10 histamine H1 receptor antagonists in two functional models. Eur J Pharmacol 2005;506:257-64
   PubMed Web of Science ®Google Scholar
• Cardelús I, Antón F, Beleta J, Palacios JM. Anticholinergic effects of desloratadine, the major metabolite of loratadine, in rabbit and guinea-pig iris smooth muscle. Eur J Pharmacol 1999;374:249-54
   PubMed Web of Science ®Google Scholar
• Liu H, Farley JM. Effects of first and second generation antihistamines on muscarinic induced mucus gland cell ion transport. BMC Pharmacol 2005;5:8
   PubMedGoogle Scholar
• Berger WE, Lumry WR, Meltzer EO, Pearlman DS. Efficacy of desloratadine, 5 mg, compared with fexofenadine, 180 mg, in patients with symptomatic seasonal allergic rhinitis. Allergy Asthma Proc 2006;27(3):214-23
   PubMed Web of Science ®Google Scholar
• Prenner BM, Capano D, Harris AG. Efficacy and tolerability of loratadine versus fexofenadine in the treatment of seasonal allergic rhinitis: a double-blind comparison with crossover treatment of nonresponders. Clin Ther 2000;22(6):760-9
   PubMed Web of Science ®Google Scholar
• Wilson AM, Haggart K, Sims EJ, Lipworth BJ. Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin Exp Allergy 2002;32:1504-9
   PubMed Web of Science ®Google Scholar
• Lee DKC, Gardiner M, Haggart K, et al. Comparative effects of desloratadine, fexofenadine, and levocetirizine on nasal adenosine monophosphate challenge in patients with perennial allergic rhinitis. Clin Exp Allergy 2004;34:650-3
   PubMed Web of Science ®Google Scholar
• Handa S, Dogra S, Kumar B. Comparative efficacy of cetirizine and fexofenadine in the treatment of chronic idiopathic urticaria. J Dermatol Treat 2004;15:55-7
   PubMedGoogle Scholar
• Meltzer EO, Scheinmann P, Rosado-Pinto JE, et al. Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis–a pooled analysis of three studies. Pediatr Allergy Immunol 2004;15:253-60
   PubMed Web of Science ®Google Scholar
• Milgrom H, Kittner B, Lanier R, Hampel FC. Safety and tolerability of fexofenadine for the treatment of allergic rhinitis in children 2 to 5 years old. Ann Allergy Asthma Immunol 2007;99:358-63
   PubMed Web of Science ®Google Scholar
• Dresser GK, Bailey DG. The effects of fruit juices on drug disposition: a new model for drug interactions. Eur J Clin Invest 2003;33(Suppl):10-6
   PubMed Web of Science ®Google Scholar
• Hofmann U, Seiler M, Drescher S, et al. Determination of fexofenadine in human plasma and urine by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002;766:227-33
   PubMed Web of Science ®Google Scholar